Germanium (68Ge) chloride/gallium (68Ga) chloride
| Combination of | |
|---|---|
| Germanium (68Ge) chloride | Radionuclide |
| Gallium (68Ga) chloride | Radionuclide |
| Clinical data | |
| Trade names | Galenvita |
| ATC code |
|
| Legal status | |
| Legal status | |
Germanium (68Ge) chloride/gallium (68Ga) chloride is a radionuclide generator. It is a combination of germanium (68
Ge) chloride and gallium (68
Ga) chloride.
Medical uses
The combination is indicated for in vitro radiolabeling of various kits for radiopharmaceutical preparation developed and approved for radiolabeling with such eluate, to be used for positron emission tomography (PET) imaging.[1][2]
Society and culture
Legal status
In November 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended granting a marketing authorization for GalenVita (germanium (68Ge) chloride / gallium (68Ga) chloride), a radionuclide generator.[3] GalenVita is used to produce gallium (68Ga) chloride solution, that is used to label carrier molecules used for positron emission tomography (PET) diagnostic imaging of different types of tumors.[3][4] The combination was authorized for medical use in the European Union in January 2026.[1][2]
Names
The combination is sold under the brand name GalenVita.[1][2]
References
- 1 2 3 4 "GalenVita EPAR". European Medicines Agency (EMA). 14 November 2025. Retrieved 16 February 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- 1 2 3 4 "GalenVita Product information". Union Register of medicinal products. 9 January 2026. Retrieved 16 February 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- 1 2 "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025". European Medicines Agency (EMA). 14 November 2025. Retrieved 16 February 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ Balzano N (December 2025). Grolla A (ed.). "GalenVita" (PDF). SIF Pharma News.
Positive opinion for radiolabeling of other medicinal products